Selected research
Industry Research
Dalteparin Sodium Industry Research Report 2026
Market perspective
The global Dalteparin Sodium market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Dalteparin Sodium is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Dalteparin Sodium is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Dalteparin Sodium is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Dalteparin Sodium include Aspen Oss, Opocrin, Pharma Action, SPL, Yino Pharma Limited, Baxter, Changshan Biochemical, Changzhou Qianhong Bio-pharma and Dongcheng Biochemicals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dalteparin Sodium market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dalteparin Sodium Market by Company
Aspen Oss
Opocrin
Pharma Action
SPL
Yino Pharma Limited
Baxter
Changshan Biochemical
Changzhou Qianhong Bio-pharma
Dongcheng Biochemicals
Dongying Tiandong Pharmaceutical
Pfizer
Nanjing King-friend
Xinbai Pharmaceuticals
Shenzhen Hepalink
Sichuan Deebio
Dalteparin Sodium Segment by Type
Tablet Dalteparin Sodium
Injection Dalteparin Sodium
Dalteparin Sodium Segment by Application
Myocardial Infarction Treatment
Hemodialysis
Others
Dalteparin Sodium Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dalteparin Sodium market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dalteparin Sodium and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dalteparin Sodium.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dalteparin Sodium manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dalteparin Sodium by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dalteparin Sodium in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet Dalteparin Sodium
- Injection Dalteparin Sodium
Applications
- Myocardial Infarction Treatment
- Hemodialysis
- Others
Companies covered
- Aspen Oss
- Opocrin
- Pharma Action
- SPL
- Yino Pharma Limited
- Baxter
- Changshan Biochemical
- Changzhou Qianhong Bio-pharma
- Dongcheng Biochemicals
- Dongying Tiandong Pharmaceutical
- Pfizer
- Nanjing King-friend
- Xinbai Pharmaceuticals
- Shenzhen Hepalink
- Sichuan Deebio
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dalteparin Sodium Market Size (2021-2032)
- 2.2.2 Global Dalteparin Sodium Sales (2021-2032)
- 2.2.3 Global Dalteparin Sodium Market Average Price (2021-2032)
- 2.3 Dalteparin Sodium by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablet Dalteparin Sodium
- 2.3.3 Injection Dalteparin Sodium
- 2.4 Dalteparin Sodium by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Myocardial Infarction Treatment
- 2.4.3 Hemodialysis
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dalteparin Sodium Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dalteparin Sodium Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Dalteparin Sodium Revenue of Manufacturers (2021-2026)
- 3.4 Global Dalteparin Sodium Average Price by Manufacturers (2021-2026)
- 3.5 Global Dalteparin Sodium Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dalteparin Sodium, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dalteparin Sodium, Product Type & Application
- 3.8 Global Manufacturers of Dalteparin Sodium, Established Date
- 3.9 Global Dalteparin Sodium Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Aspen Oss
- 4.1.1 Aspen Oss Company Information
- 4.1.2 Aspen Oss Business Overview
- 4.1.3 Aspen Oss Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Aspen Oss Dalteparin Sodium Product Portfolio
- 4.1.5 Aspen Oss Recent Developments
- 4.2 Opocrin
- 4.2.1 Opocrin Company Information
- 4.2.2 Opocrin Business Overview
- 4.2.3 Opocrin Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Opocrin Dalteparin Sodium Product Portfolio
- 4.2.5 Opocrin Recent Developments
- 4.3 Pharma Action
- 4.3.1 Pharma Action Company Information
- 4.3.2 Pharma Action Business Overview
- 4.3.3 Pharma Action Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pharma Action Dalteparin Sodium Product Portfolio
- 4.3.5 Pharma Action Recent Developments
- 4.4 SPL
- 4.4.1 SPL Company Information
- 4.4.2 SPL Business Overview
- 4.4.3 SPL Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 SPL Dalteparin Sodium Product Portfolio
- 4.4.5 SPL Recent Developments
- 4.5 Yino Pharma Limited
- 4.5.1 Yino Pharma Limited Company Information
- 4.5.2 Yino Pharma Limited Business Overview
- 4.5.3 Yino Pharma Limited Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Yino Pharma Limited Dalteparin Sodium Product Portfolio
- 4.5.5 Yino Pharma Limited Recent Developments
- 4.6 Baxter
- 4.6.1 Baxter Company Information
- 4.6.2 Baxter Business Overview
- 4.6.3 Baxter Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Baxter Dalteparin Sodium Product Portfolio
- 4.6.5 Baxter Recent Developments
- 4.7 Changshan Biochemical
- 4.7.1 Changshan Biochemical Company Information
- 4.7.2 Changshan Biochemical Business Overview
- 4.7.3 Changshan Biochemical Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Changshan Biochemical Dalteparin Sodium Product Portfolio
- 4.7.5 Changshan Biochemical Recent Developments
- 4.8 Changzhou Qianhong Bio-pharma
- 4.8.1 Changzhou Qianhong Bio-pharma Company Information
- 4.8.2 Changzhou Qianhong Bio-pharma Business Overview
- 4.8.3 Changzhou Qianhong Bio-pharma Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Changzhou Qianhong Bio-pharma Dalteparin Sodium Product Portfolio
- 4.8.5 Changzhou Qianhong Bio-pharma Recent Developments
- 4.9 Dongcheng Biochemicals
- 4.9.1 Dongcheng Biochemicals Company Information
- 4.9.2 Dongcheng Biochemicals Business Overview
- 4.9.3 Dongcheng Biochemicals Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Dongcheng Biochemicals Dalteparin Sodium Product Portfolio
- 4.9.5 Dongcheng Biochemicals Recent Developments
- 4.10 Dongying Tiandong Pharmaceutical
- 4.10.1 Dongying Tiandong Pharmaceutical Company Information
- 4.10.2 Dongying Tiandong Pharmaceutical Business Overview
- 4.10.3 Dongying Tiandong Pharmaceutical Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Dongying Tiandong Pharmaceutical Dalteparin Sodium Product Portfolio
- 4.10.5 Dongying Tiandong Pharmaceutical Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Dalteparin Sodium Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 Nanjing King-friend
- 4.12.1 Nanjing King-friend Company Information
- 4.12.2 Nanjing King-friend Business Overview
- 4.12.3 Nanjing King-friend Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Nanjing King-friend Dalteparin Sodium Product Portfolio
- 4.12.5 Nanjing King-friend Recent Developments
- 4.13 Xinbai Pharmaceuticals
- 4.13.1 Xinbai Pharmaceuticals Company Information
- 4.13.2 Xinbai Pharmaceuticals Business Overview
- 4.13.3 Xinbai Pharmaceuticals Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Xinbai Pharmaceuticals Dalteparin Sodium Product Portfolio
- 4.13.5 Xinbai Pharmaceuticals Recent Developments
- 4.14 Shenzhen Hepalink
- 4.14.1 Shenzhen Hepalink Company Information
- 4.14.2 Shenzhen Hepalink Business Overview
- 4.14.3 Shenzhen Hepalink Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Shenzhen Hepalink Dalteparin Sodium Product Portfolio
- 4.14.5 Shenzhen Hepalink Recent Developments
- 4.15 Sichuan Deebio
- 4.15.1 Sichuan Deebio Company Information
- 4.15.2 Sichuan Deebio Business Overview
- 4.15.3 Sichuan Deebio Dalteparin Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Sichuan Deebio Dalteparin Sodium Product Portfolio
- 4.15.5 Sichuan Deebio Recent Developments
5 Global Dalteparin Sodium Market Scenario by Region
- 5.1 Global Dalteparin Sodium Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dalteparin Sodium Sales by Region: 2021-2032
- 5.2.1 Global Dalteparin Sodium Sales by Region: 2021-2026
- 5.2.2 Global Dalteparin Sodium Sales by Region: 2027-2032
- 5.3 Global Dalteparin Sodium Revenue by Region: 2021-2032
- 5.3.1 Global Dalteparin Sodium Revenue by Region: 2021-2026
- 5.3.2 Global Dalteparin Sodium Revenue by Region: 2027-2032
- 5.4 North America Dalteparin Sodium Market Facts & Figures by Country
- 5.4.1 North America Dalteparin Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dalteparin Sodium Sales by Country (2021-2032)
- 5.4.3 North America Dalteparin Sodium Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Dalteparin Sodium Market Facts & Figures by Country
- 5.5.1 Europe Dalteparin Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dalteparin Sodium Sales by Country (2021-2032)
- 5.5.3 Europe Dalteparin Sodium Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Dalteparin Sodium Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dalteparin Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dalteparin Sodium Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dalteparin Sodium Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dalteparin Sodium Market Facts & Figures by Country
- 5.7.1 South America Dalteparin Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dalteparin Sodium Sales by Country (2021-2032)
- 5.7.3 South America Dalteparin Sodium Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Dalteparin Sodium Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dalteparin Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dalteparin Sodium Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dalteparin Sodium Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Dalteparin Sodium Sales by Type (2021-2032)
- 6.1.1 Global Dalteparin Sodium Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Dalteparin Sodium Sales Market Share by Type (2021-2032)
- 6.2 Global Dalteparin Sodium Revenue by Type (2021-2032)
- 6.2.1 Global Dalteparin Sodium Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dalteparin Sodium Revenue Market Share by Type (2021-2032)
- 6.3 Global Dalteparin Sodium Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dalteparin Sodium Sales by Application (2021-2032)
- 7.1.1 Global Dalteparin Sodium Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Dalteparin Sodium Sales Market Share by Application (2021-2032)
- 7.2 Global Dalteparin Sodium Revenue by Application (2021-2032)
- 7.2.1 Global Dalteparin Sodium Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dalteparin Sodium Revenue Market Share by Application (2021-2032)
- 7.3 Global Dalteparin Sodium Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dalteparin Sodium Value Chain Analysis
- 8.1.1 Dalteparin Sodium Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dalteparin Sodium Production Mode & Process
- 8.2 Dalteparin Sodium Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dalteparin Sodium Distributors
- 8.2.3 Dalteparin Sodium Customers
9 Global Dalteparin Sodium Analyzing Market Dynamics
- 9.1 Dalteparin Sodium Industry Trends
- 9.2 Dalteparin Sodium Industry Drivers
- 9.3 Dalteparin Sodium Industry Opportunities and Challenges
- 9.4 Dalteparin Sodium Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst